Recital 3, Regulation (EU) 2021/824

In forcesince 21 May 2021

In addition, Implementing Regulation (EU) No 820/2011 required the applicant to submit confirmatory information as regards the relevance of the metabolites MT1 MT13, MT14 and of the unidentified metabolites LM1, LM2, LM3, LM4, LM5 and LM6 with respect to cancer, if terbuthylazine was classified under Regulation (EC) No 1272/2008 of the European Parliament and of the Council [Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (OJ L 353, 31.12.2008, p. 1).] as ‘suspected of causing cancer’.